PCR in Screening and Diagnostics: Market Developments, Growth Areas and Opportunities

Date: June 3, 2013
Pages: 168
Price:
US$ 2,794.00
License [?]:
Publisher: Biopharm Reports
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: P98DB30CBB5EN
Leaflet:

Download PDF Leaflet

PCR in Screening and Diagnostics: Market Developments, Growth Areas and Opportunities
Summary: This market analysis was carried out to provide business information to developers, manufacturers and suppliers in the PCR clinical and diagnostics field. Its findings include:
  • Marketing and sales opportunities
  • End-user purchasing decisions
  • Market growth and shrinkage
  • Innovation and new product opportunities
This study was conducted through specialist groups of experienced clinical and laboratory PCR end-users and its findings are therefore based on 'real world' market data.

Market Analysis and Opportunities

A competitive market analysis of current practices and future developments across 25 key market areas in the PCR screening and diagnostics field. Examples include
  • PCR Techniques: Which PCR screening and diagnostics techniques are the market leaders and what changes do end-users predict over the next three years. Which PCR clinical and diagnostics techniques are growing and which are declining?
  • PCR Applications: Which PCR screening and diagnostics applications are the market leaders and what changes do end-users predict over the next three years. Which PCR clinical and diagnostics applications are growing and which are reducing?
  • Suppliers: Who are the major company suppliers in the PCR screening and diagnostics field and who do PCR clinical and diagnostics end-users plan to purchase from over the next three years. Who are the top ten suppliers in this field, and what changes are predicted over the next three years.
  • Opportunities: The findings of this study are analysed to identify opportunities to suppliers in the PCR screening and diagnostics field, in the 'Market Areas' indicated below.
Overview

PCR is used in a wide variety of molecular biology applications, including sequencing, genetic fingerprinting, cloning, disease research, diagnostics, drug discovery, disease biomarkers and forensics. Today, this technique continues to grow and some estimates suggest that by 2015 global markets for this technique will exceed $27 billion. Biopharm Reports has carried out a market study of this field, which investigated the use of PCR in screening and diagnostics. This involved the participation of 173 specialist end-users in 50 countries. This study was carried out to identify market developments and growth areas, and the opportunities these offer to developers and vendors in this field.

Market areas investigated in this study included current and future techniques and applications, PCR suppliers, end-users’ plans for using PCR in screening and diagnostics over the next three years, as well as the PCR companies they anticipate purchasing from. Other market areas included preferred PCR systems, new developments, emerging applications, the strengths and weaknesses of current systems, innovation, budgets and expenditure, consumables, software, sample preparation and other areas. Further details are presented below.

Market Areas
  • Current PCR techniques: Current use of more than 40 PCR techniques in screening or diagnostics by end-users, each ranked according to their competitive position. PCR techniques considered include Allele Specific PCR, Arbitrarily Primed PCR (APPCR), Assembly PCR (Polymerase Cycling Assembly, PCA), Asymmetric PCR (A PCR), Bead Emulsion Amplification PCR (BEA), Classical PCR, Colony PCR, Degenerate Oligonucleotide PCR (DOPPCR), Digital PCR (dPCR), Helicase Dependent Amplification (HDA), Hot start PCR, Hyper PCR, Immunocapture PCR, In Silico PCR, Inter Sequence Specific PCR (ISSR), Inverse PCR, Ligation Mediated PCR, Long PCR, Loop Mediated Isothermal Amplification (LAMP), Methylation Specific PCR (MSP), Miniprimer PCR, Multiplex Ligation Dependent Probe Amplification (MLPA), Multiplex PCR, Nested PCR, Overlap Extension PCR ( Splicing by overlap extension, SOE), PANAC (Single Reaction Real Time PCR), PCR array, PCR Denaturing Gradient Gel Electrophoresis (PCR DGGE), PCR Restriction Fragment Length Polymorphism (PCRRFLP), Quantitative PCR (qPCR), Random Amplified Polymorphic DNA (RAPD), Rapid Amplification of cDNA ENDS PCR (RACE PCR), Reverse Transcription PCR (RTPCR), Single Molecule PCR, Single Specific Primer Polymerase, Chain Reaction (SSPPCR), Solid Phase PCR, Stem loop RT PCR, Stepdown PCR, Taqman, Temporal Temperature Gradient Gel Electrophoresis (PCRTTGE), Thermal Asymmetric Interlaced PCR (TAILPCR), Touchdown PCR, Universal Fast Walking or other.
  • Future PCR techniques: Future anticipated use of more than 40 PCR techniques in screening or diagnostics by end-users over the next three years, each ranked according to their competitive position. PCR techniques considered include Allele Specific PCR, Arbitrarily Primed PCR (APPCR), Assembly PCR (Polymerase Cycling Assembly, PCA), Asymmetric PCR (A PCR), Bead Emulsion Amplification PCR (BEA), Classical PCR, Colony PCR, Degenerate Oligonucleotide PCR (DOPPCR), Digital PCR (dPCR), Helicase Dependent Amplification (HDA), Hot start PCR, Hyper PCR, Immunocapture PCR, In Silico PCR, Inter Sequence Specific PCR (ISSR), Inverse PCR, Ligation Mediated PCR, Long PCR, Loop Mediated Isothermal Amplification (LAMP), Methylation Specific PCR (MSP), Miniprimer PCR, Multiplex Ligation Dependent Probe Amplification (MLPA), Multiplex PCR, Nested PCR, Overlap Extension PCR ( Splicing by overlap extension, SOE), PANAC (Single Reaction Real Time PCR), PCR array, PCR Denaturing Gradient Gel Electrophoresis (PCR DGGE), PCR Restriction Fragment Length Polymorphism (PCRRFLP), Quantitative PCR (qPCR), Random Amplified Polymorphic DNA (RAPD), Rapid Amplification of cDNA ENDS PCR (RACE PCR), Reverse Transcription PCR (RTPCR), Single Molecule PCR, Single Specific Primer Polymerase, Chain Reaction (SSPPCR), Solid Phase PCR, Stem loop RT PCR, Stepdown PCR, Taqman, Temporal Temperature Gradient Gel Electrophoresis (PCRTTGE), Thermal Asymmetric Interlaced PCR (TAILPCR), Touchdown PCR, Universal Fast Walking or other.
  • Current PCR applications: Current use of 15 PCR applications in screening or diagnostics by end-users, each ranked according to their competitive position. Application considered were allele size detection for human ID STR typing, bacterial tipification (REPPCR), cell-free DNA mutations, cloning, commensal bacteria detection / quantification, community profiling, detection of antimicrobial resistance genes, detection of specific microbial 16S rRNA genes, diagnostics, drug treatment dosage prediction, drug treatment type prediction, fungal species detection, gene expression (mRNA), gene mutations and alterations, generating genetic probes, genetic mapping, genetic material amplification, sequencing, haplotypes, immunocapture PCR mediated virion detection, microbial populations, MicroRNA quantification, pathogen detection/identification, quantitative analysis of gene abundance, site-directed mutagenesis, tissue typing or other.
  • Future PCR applications: Application considered were allele size detection for human ID STR typing, bacterial tipification (REPPCR), cell-free DNA mutations, cloning, commensal bacteria detection / quantification, community profiling, detection of antimicrobial resistance genes, detection of specific microbial 16S rRNA genes, diagnostics, drug treatment dosage prediction, drug treatment type prediction, fungal species detection, gene expression (mRNA), gene mutations and alterations, generating genetic probes, genetic mapping, genetic material amplification, sequencing, haplotypes, immunocapture PCR mediated virion detection, microbial populations, MicroRNA quantification, pathogen detection/identification, quantitative analysis of gene abundance, site-directed mutagenesis, tissue typing or other.
  • Biomarker identity: The identities of the main biomarkers investigated using PCR.
  • Biomarker types: The main biomarker types investigated using PCR, including gene variations (mutations/polymorphisms), DNA methylation, gene copy number, gene expression, SNPs, mRNA, MicroRNA, alternative spliced variants or other.
  • Biomarker utility: The main clinical utilities of biomarkers investigated using PCR, including disease prognosis, disease susceptibility or risk, disease stage or severity, drug type therapy decision-making, drug type therapy dose, drug discovery, early detection of disease, clinical trial endpoint, guiding treatment, response to therapy, safety or toxicity factors or other areas.
  • Current company suppliers: End-users’ preferred current company suppliers for their PCR, including Abbott, Agilent, Applied Biosystems, Becton Dickinson, Bioline, Biometra, Biorad, Biotium, Biozyme, Cepheid, Eppendorf, ESCO, Euroclone, Eurogentec, Fermentas, Finnzymes, Fluidigm, GE Healthcare, Genework, Hain Life sciences, Idaho, Integrated Data Technologies, Invitrogen, Kapa Biosystems, Life Technologies, Luminex, Machery Nagel, MJ Research, New England BioLabs, Perkin Elmer, Promega, Qiagen, Quanta Bioscience, Roche, SensoQuest, Siemens, Sigma Genosys, Stratagene, Takara, Thermofisher or others.
  • Future company suppliers: End-user’s anticipated preferred company suppliers for their PCR over the next three years, including Abbott, Agilent, Applied Biosystems, Becton Dickinson, Bioline, Biometra, Biorad, Biotium, Biozyme, Cepheid, Eppendorf, ESCO, Euroclone, Eurogentec, Fermentas, Finnzymes, Fluidigm, GE Healthcare, Genework, Hain Life sciences, Idaho, Integrated Data Technologies, Invitrogen, Kapa Biosystems, Life Technologies, Luminex, Machery Nagel, MJ Research, New England BioLabs, Perkin Elmer, Promega, Qiagen, Quanta Bioscience, Roche, SensoQuest, Siemens, Sigma Genosys, Stratagene, Takara, Thermofisher or others.
  • Preferred instrument: End-users preferred PCR instrument (from their preferred supplier) in the PCR field.
  • Strengths: The strengths of end-user’s preferred instrument in the PCR field (how is it meeting their needs in this area).
  • Weaknesses: The weaknesses of end-users preferred instrument in the PCR field (how is it failing to meet their needs in this area).
  • Bioinformatics software: End-users preferred bioinformatics software in the PCR field.
  • Required innovations: End-user’s views (rated on a scale of 1-10) on the PCR areas where innovations is most required. Innovation areas considered were sample preparation, ancillary techniques, PCR (qualitative) selectivity, PCR (quantitative) sensitivity, PCR reproducibility, PCR qualitative/quantitative capability, PCR robustness (ruggedness), detection methods, automation, speed or sample throughput, specialist data control systems, specialist bioinformatics systems or other.
  • Samples: End-user’s main samples analysed using PCR, including animal tissues, cell isolates, cells cerebrospinal fluid, genetic material, human tissues, In-vitro biological solutions, microbiological materials, plasma, saliva, serum, urine, whole blood or other.
  • Sample preparation: End-user’s preferred sample preparation technique.
  • Recent Innovation: End-user’s views on the most important PCR innovations in their field over the last three years.
  • Financial Budget: End-user’s annual financial budgets relating to their use of PCR in screening and diagnostics.
  • Cost per sample: End-users average costs per sample, using PCR in screening and diagnostics.
  • Current Budget breakdown: End user’s current budget breakdown for the use of PCR in screening and diagnostics, relating to reagents and consumables, system control (data handling) software, data analysis (offline) software, PCR instruments, sample preparation and related instrumentation, ancillary systems/instrumentation, general overheads, instrument servicing/repair, staff salaries and other areas.
  • Future Budget breakdown: End user’s anticipated future budget breakdown for the use of PCR in screening and diagnostics, relating to reagents and consumables, system control (data handling) software, data analysis (offline) software, PCR instruments, sample preparation and related instrumentation, ancillary systems/instrumentation, general overheads, instrument servicing/repair, staff salaries and other areas.
  • Overall budget: End-user’s estimates of by how much they anticipate their overall annual financial budget for the use of PCR in screening and diagnostics will change, either increase or decrease, over the next three years.
  • Consumables: End-users top three consumables in terms of overall costs, that are directly associated with their PCR work in screening and diagnostics.
  • PCR activities: End-user’s PCR activities in screening and diagnostics, relating to the running of routine PCR tests for clinical decision-making, the development or validation of PCR tests and the qualitative discovery of disease biomarkers using PCR.
  • Organisation types: Organisation types in this study included universities, research Institutes, small companies, medium sized companies, large international company, clinics, hospitals, government organisations, veterinary organisation and others.
  • Fields: Fields types of participants in this study included biotechnology, clinical, hospital, government, healthcare, pharmaceuticals, research institute, university or other.
  • Therapeutic Areas: End-users’ DNA sequencing activities in terms of their general therapeutic area, including arthritis, autoimmune diseases, done metabolism, cancer, cardiovascular, central nervous system, endocrine, gastrointestinal, genito-urinary system, haematology, infections, inflammation, metabolic disorders, musculoskeletal disorders, nutrition, obstetrics and gynaecology, ophthalmology, pain, respiratory, skin or other.
  • Purpose: End-users’ underlying reasons for using PCR in screening or diagnostics across 12 areas, namely clinical research, routine diagnostics, routine screening, clinical trials, treatment decisions, treatment monitoring, diagnostics research, disease research, drug R&D, drug targets, pathology, toxicology or other.
EXECUTIVE SUMMARY

CHAPTER 1 INTRODUCTION

CHAPTER 2 STUDY PARTICIPANTS

2.1 This Chapter
2.2 Countries
2.3 Regions
2.4 Organisation Types
2.5 Fields
2.6 PCR Activities
2.7 Participants
2.8 Discussion
  Figure 2.1 Countries of individuals who participated in PCR 2013 CLIN
  Figure 2.2 Global regions of individuals who participated in PCR 2013 CLIN.
  Figure 2.3 Organisation types of individuals who participated in PCR 2013 CLIN
  Figure 2.4 Fields of individuals who participated in PCR 2013 CLIN
  Table 2.1 Countries of individuals who participated in PCR 2013 CLIN
  Table 2.2 Global regions of individuals who participated in PCR 2013 CLIN
  Table 2.3 Organisation types of individuals who participated in PCR 2013 CLIN

CHAPTER 3 PCR TECHNIQUES

3.1 This Chapter
3.2 Current Techniques
3.3 Future Techniques
3.4 Discussion
  Figure 3.1 Top ten currently used PCR techniques, indicated by individuals who participated in PCR 2013 CLIN
  Table 3.1 Currently used PCR techniques, indicated by individuals who participated in PCR 2013 CLIN
  Figure 3.2 Other currently used PCR techniques, indicated by individuals who participated in PCR 2013 CLIN
  Table 3.2 Other currently used PCR techniques, indicated by individuals who participated in PCR 2013 CLIN
  Figure 3.3 Top ten PCR techniques that end-users anticipate they will be using over the next three years (2013 To 2016), indicated by individuals who participated in PCR 2013 CLIN
  Table 3.3 PCR techniques that end-users anticipate they will be using over the next three years (2013 To 2016), indicated by individuals who participated in PCR 2013 CLIN
  Figure 3.4 Other PCR techniques that end-users anticipate they will be using over the next three years (2013 To 2016), indicated by individuals who participated in PCR 2013 CLIN
  Table 3.4 Other PCR techniques that end-users anticipate they will be using over the next three years (2013 To 2016), indicated by individuals who participated PCR 2013 CLIN

CHAPTER 4 PCR APPLICATIONS

4.1 This Chapter
4.2 Current Applications
4.3 Future Applications
4.4 Discussion
  Figure 4.1 Top ten currently used PCR applications, indicated by individuals who participated in PCR 2013 CLIN
  Table 4.1 Currently used PCR applications, indicated by individuals who participated in PCR 2013 CLIN
  Figure 4.2 Other currently used PCR applications, indicated by individuals who participated in PCR 2013 CLIN
  Table 4.2 Other currently used PCR applications, indicated by individuals who participated in PCR 2013 CLIN
  Figure 4.3 Top ten PCR applications that end-users anticipate they will be using over the next three years (2013 To 2016), indicated by individuals who participated in PCR 2013 CLIN
  Table 4.3 PCR applications that end-users anticipate they will be using over the next three years (2013 To 2016), indicated by individuals who participated in PCR 2013 CLIN
  Figure 4.4 Other PCR applications that end-users anticipate they will be using over the next three years (2013 To 2016), indicated by individuals who participated in PCR 2013 CLIN
  Table 4.4 Other PCR applications that end-users anticipate they will be using over the next three years (2013 To 2016), indicated by individuals who participated in PCR 2013 CLIN

CHAPTER 5 COMPANIES

5.1 This Chapter
5.2 Current Companies
5.3 Future Companies
5.4 Discussion
  Figure 5.1 Top ten PCR company suppliers, currently used by individuals who participated in PCR 2013 CLIN
  Table 5.1 PCR company suppliers, currently used by individuals who participated in PCR 2013 CLIN
  Figure 5.2 Other PCR company suppliers, currently used by individuals who participated in PCR 2013 CLIN
  Table 5.2 Other PCR company suppliers, currently used by individuals who participated in PCR 2013 CLIN
  Figure 5.3 Top ten PCR company suppliers that end-users anticipate they will be using over the next three years (2013 To 2016), indicated by individuals who participated in PCR 2013 CLIN
  Table 5.3 PCR company suppliers that end-users anticipate they will be using over the next three years (2013 To 2016), indicated by individuals who participated in PCR 2013 CLIN
  Figure 5.4 Other PCR company suppliers that end-users anticipate they will be using over the next three years (2013 To 2016), indicated by individuals who participated in PCR 2013 CLIN
  Table 5.4 Other PCR company suppliers that end-users anticipate they will be using over the next three years (2013 To 2016), indicated by individuals who participated in PCR 2013 CLIN

CHAPTER 6 PREFERRED COMPANIES AND PRODUCTS

6.1 This Chapter
6.2 Preferred Companies
6.3 Preferred products
6.4 Strengths
6.5 Weaknesses
6.6 Discussion
  Figure 6.1 Top ten preferred suppliers in the PCR field, indicated by individuals who participated in PCR 2013 CLIN
  Table 6.1 Preferred suppliers in the PCR field, indicated by individuals who participated in PCR 2013 CLIN
  Figure 6.2 Other preferred suppliers in the PCR field, indicated by individuals who participated in PCR 2013 CLIN
  Table 6.2 Other preferred suppliers in the PCR field, indicated by individuals who participated in PCR 2013 CLIN
  Figure 6.3 Top ten preferred products in the PCR field, indicated by individuals who participated in PCR 2013 CLIN
  Table 6.3 Preferred products in the PCR field, indicated by individuals who participated in PCR 2013 CLIN
  Figure 6.4 Other preferred products in the PCR field, indicated by individuals who participated in PCR 2013 CLIN
  Table 6.4 Other Top preferred products in the PCR field, indicated by individuals who participated in PCR 2013 CLIN
  Figure 6.5 Top ten strengths of preferred products in the PCR field, indicated by individuals who participated in PCR 2013 CLIN
  Table 6.5 Strengths of preferred products in the PCR field, indicated by individuals who participated in PCR 2013 CLIN
  Figure 6.6 Other strengths of preferred products in the PCR field, indicated by individuals who participated in PCR 2013 CLIN
  Table 6.6 Other strengths of preferred products in the PCR field, indicated by individuals who participated in PCR 2013 CLIN
  Figure 6.7 Top ten weaknesses of preferred products in the PCR field, indicated by individuals who participated in PCR 2013 CLIN
  Table 6.7 Weaknesses of preferred products in the PCR field, indicated by individuals who participated in PCR 2013 CLIN
  Figure 6.8 Other weaknesses of preferred products in the PCR field, indicated by individuals who participated in PCR 2013 CLIN
  Table 6.8 Other weaknesses of preferred products in the PCR field, indicated by individuals who participated in PCR 2013 CLIN

CHAPTER 7 PCR EXPENDITURE AND BUDGETS

7.1 This Chapter
7.2 Current Financial budget
7.3 Future Expenditure
7.4 Future General Budget
  Figure 7.1 Annual financial budgets for PCR studies, indicated by individuals who participated in PCR 2013 CLIN
  Table 7.1 Annual financial budgets for PCR studies, indicated by individuals who participated in PCR 2013 CLIN
  Figure 7.2 The breakdown of current financial budgets for PCR studies, indicated by individuals who participated in PCR 2013 CLIN
  Table 7.2 The breakdown of current financial budgets for PCR studies, indicated by individuals who participated in PCR 2013 CLIN
  Figure 7.3 Cost per sample for PCR studies, indicated by individuals who participated in PCR 2013 CLIN
  Table 7.3 Cost per sample for PCR studies, indicated by individuals who participated in PCR 2013 CLIN
  Figure 7.4 The anticipated future breakdown of financial budgets (over the next three years, 2013 To 2016) for PCR studies, indicated by individuals who participated in PCR 2013 CLIN
  Table 7.4 The anticipated future breakdown of financial budgets (over the next three years, 2013 To 2016) for PCR studies, indicated by individuals who participated in PCR 2013 CLIN

CHAPTER 8 PURPOSE OF PCR USE

8.1 This Chapter
8.2 Purpose
8.3 Discussion
  Figure 8.1 Top ten reasons for using PCR in the biotechnology industry, indicated by individuals who participated in PCR 2013 CLIN
  Figure 8.2 Top ten reasons for using PCR in clinics or hospitals, indicated by individuals who participated in PCR 2013 CLIN
  Figure 8.3 Top ten reasons for using PCR in hospitals, indicated by individuals who participated in PCR 2013 CLIN
  Figure 8.4 Top ten reasons for using PCR in the healthcare industry, indicated by individuals who participated in PCR 2013 CLIN
  Figure 8.5 Top ten reasons for using PCR in the pharmaceutical industry, indicated by individuals who participated in PCR 2013 CLIN
  Figure 8.6 Top ten reasons for using PCR in research institutes, indicated by individuals who participated in PCR 2013 CLIN
  Figure 8.7 Top ten reasons for using PCR in universities, indicated by individuals who participated in PCR 2013 CLIN

CHAPTER 9 SAMPLES

9.1 This Chapter
9.2 Samples
9.3 Discussion
  Figure 9.1 Top ten sample types analysed using PCR, indicated by individuals who participated in PCR 2013 CLIN
  Table 9.1 Sample types analysed using PCR, indicated by individuals who participated in PCR 2013 CLIN

CHAPTER 10 SAMPLE PREPARATION

10.1 This Chapter
10.2 Sample Preparation
10.3 Discussion
  Figure 10.1 Top sample preparation methods of PCR users who participated in PCR 2013 CLIN
  Table 10.1 Sample preparation methods of PCR users who participated in PCR 2013 CLIN
  Figure 10.2 Other sample preparation methods of PCR users who participated in PCR 2013 CLIN
  Table 10.2 Other sample preparation methods of PCR users who participated in PCR 2013 CLIN

CHAPTER 11 THERAPEUTIC AREAS

11.1 This Chapter
11.2 Therapeutic Areas
11.3 Discussion
  Figure 11.1 Top ten therapeutic areas of PCR users who participated in PCR 2013 CLIN
  Table 11.1 Therapeutic areas of PCR users who participated in PCR 2013 CLIN
  Figure 11.2 Other therapeutic areas of PCR users who participated in PCR 2013 CLIN
  Table 11.2 Other therapeutic areas of PCR users who participated in PCR 2013 CLIN

CHAPTER 12 DISEASE BIOMARKERS

12.1 This Chapter
12.2 Use of PCR
12.3 Biomarker Types
12.4 Clinical Utility
12.5 Discussion
  Figure 12.1 The use of PCR for the study of disease biomarkers, indicated by individuals who participated in PCR 2013 CLIN
  Figure 12.2 Principal disease biomarkers studied using PCR, indicated by individuals who participated in PCR 2013 CLIN
  Table 12.1 Other disease biomarkers studied using PCR, indicated by individuals who participated in PCR 2013 CLIN
  Figure 12.3 Clinical utilities of disease biomarkers studied using PCR, indicated by individuals who participated in PCR 2013 CLIN
  Table 12.2 Other clinical utilities of disease biomarkers studied using PCR, indicated by individuals who participated in PCR 2013 CLIN

CHAPTER 13 BIOINFORMATICS SOFTWARE

13.1 This Chapter
13.2 Bioinformatics Software
13.3 Discussion
  Figure 13.1 Top ten bioinformatics software system used for PCR, indicated by users who participated in PCR 2013 CLIN
  Table 13.1 Bioinformatics software system used for DNA PCR, indicated by users who participated in PCR 2013 CLIN
  Figure 13.2 Other bioinformatics software system used for PCR, indicated by users who participated in PCR 2013 CLIN
  Table 13.2 Other bioinformatics software system used for PCR, indicated by users who participated in PCR 2013 CLIN

CHAPTER 14 INNOVATION

14.1 This Chapter
14.2 Required Innovation
14.3 Recent Innovation
14.4 Future Innovation
14.5 Discussion
  Figure 14.1 Top ten most required areas of innovation in PCR, indicated by individuals who participated in PCR 2013 CLIN
  Table 14.1 Most required areas of innovation in PCR, indicated by individuals who participated in PCR 2013 CLIN
  Figure 14.2 Other required areas of innovation in PCR, indicated by individuals who participated in PCR 2013 CLIN
  Table 14.2 Other required areas of innovation in PCR, indicated by individuals who participated in PCR 2013 CLIN
  Figure 14.3 Top ten recent innovations (in the last three years) in PCR, indicated by individuals who participated in PCR 2013 CLIN
  Table 14.3 Recent innovations (in the last three years) in PCR, indicated by individuals who participated in PCR 2013 CLIN
  Figure 14.4 Top ten future anticipated innovations (in the next three years) in PCR, indicated by individuals who participated in PCR 2013 CLIN
  Table 14.4 Future anticipated innovations (in the next three years) in PCR, indicated by individuals who participated in PCR 2013 CLIN

CHAPTER 15 QUALITY CONTROL

15.1 This Chapter
15.2 Quality Control
15.3 Future Innovation
15.4 Discussion
  Figure 15.1 Top ten most commonly used quality control guidelines or procedures used in PCR analysis, indicated by individuals who participated in PCR 2013 CLIN
  Table 15.1 Quality control guidelines or procedures used in PCR analysis, indicated by individuals who participated in PCR 2013 CLIN

CHAPTER 16 PCR CONSUMABLES

CHAPTER 17 DISCUSSION

CHAPTER 18 APPENDICES

Ask Your Question

PCR in Screening and Diagnostics: Market Developments, Growth Areas and Opportunities
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: